- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
CombiMatrix Corporation (Nasdaq: CBMX) announced today that Mr. Chris Emery and Dr. Lony Lim have joined its wholly owned subsidiary, Combimatrix Molecular Diagnostics (CMDX), as Chief Operating Officer and Vice President of Operations, respectively. The tandem will use their extensive laboratory diagnostics services expertise to help implement the company's strategic initiatives and commercial expansion.
"It's an honor for me to work alongside the scientific team that's been assembled at CMDX and drive commercialization and utilization of the innovative molecular diagnostic assays that have been created here," said Emery. "Array CGH testing has been well-adopted in clinical practice in the constitutional genetics setting, and has tremendous potential to shift the paradigm in personalized treatment decision-making for cancer patients in both solid tumors and hematologic malignancies. CMDX's testing platform allows the treating physician to view common chromosomal abnormalities in conjunction with an entire genome analysis, which enables genomic instability monitoring of each patient's unique tumor. I look forward to supporting CMDX along its strategic path and I'm confident these laboratory test offerings will enhance therapeutic outcomes from both clinical and economic standpoints," Emery concluded.
Mr. Emery earned his bachelor degree from the University of California, San Diego, and his Master in Business Administration from Pepperdine University. He started his career in healthcare as a Sales Manager with Johnson & Johnson's pharmaceutical division and has since spent more than 10 years in the cancer-focused diagnostics laboratory industry. Mr. Emery was a Marketing Manager with US LABS (a division of LabCorp) and was then promoted to National Sales Manager of the Oncology sales division. Mr. Emery was Vice President of Sales & Marketing at Response Genetics, where he helped launch the company's portfolio of molecular diagnostic, personalized medicine testing. He recently consulted for Agendia, a global leader in microarray genomic profiling, as Director of Clinical Trials.
Further supporting CMDX's strategic initiatives will be new Vice President of Operations, Dr. Lony Lim. "I'm excited to come on board in order to expand and optimize testing that will help physicians make more informed treatment decisions with regard to each patient's individualized situation," said Dr. Lim. "CMDX is dedicated to assuring that the highest level of laboratory practices are met and has a continued focus on quality test-result reporting, competitive turn-around time, and regulatory compliance," said Dr. Lim. "We are increasing efficiencies and supplementing current testing modalities to ensure that our overall offering provides unprecedented clinical value. Upcoming laboratory facility expansion and future multi-site operations will allow CMDX to further extend services to both physicians and patients."
Dr. Lim brings a wealth of experience in the Clinical Reference Laboratory, Anatomic Pathology and In-Vitro Diagnostics industries. He served as Director of Scientific Affairs, Director of Flow Cytometry and Director of Anatomic Pathology at US LABS and Scientific Director - Division of Immunology at AmeriPath Specialty Laboratories. He was one of the pioneers in the genesis of Luminex Corporation's Multi-Analyte Profiling technology (xMAP(R)) and was instrumental in delivering the initial clinical acceptance of xMAP(R) technology, which is now widely used in both protein and molecular profiling applications across numerous clinical laboratories.
Dr. Lim received both his B.S. and his Ph.D. from the University of Wisconsin-Madison and completed the William McLendon Clinical Immunology Fellowship at the University of North Carolina Hospitals, Chapel Hill. He has professional memberships in ASCO, ASH, ASCP, NSH, AACC, ASM, and AMLI. He has published and presented numerous scientific papers and abstracts.
"I'm delighted with the addition of Mr. Emery and Dr. Lim to our senior management," said Dr. Mansoor Mohammed, President and CEO of CMDX. "Chris and Lony perfectly complement our existing staff and ideally position us for our aggressive growth trajectory."
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.
About CombiMatrix Corporation
CombiMatrix Corporation is a diversified biotechnology business that develops proprietary technologies, including products and services in the areas of drug development, genetic analysis, molecular diagnostics, nanotechnology and defense and homeland security markets, as well as in other potential markets where our products and services could be utilized. The technologies we have developed include a platform technology to rapidly produce user-defined, in-situ synthesized, oligonucleotide arrays for use in identifying and determining the roles of genes, gene mutations and proteins. This technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology. Other technologies include proprietary molecular synthesis and screening methods for the discovery of potential new drugs. Combimatrix Molecular Diagnostics, Inc. ("CMDX"), our wholly owned subsidiary located in Irvine, California, has developed capabilities of producing arrays that utilize bacterial artificial chromosomes, which also enable genetic analysis. CMDX functions primarily as a diagnostics reference laboratory. Leuchemix Inc. ("Leuchemix"), a minority owned subsidiary, is developing a series of compounds to address a number of oncology-related diseases. Leuchemix's first compound has entered initial clinical trials.
Additional information about CombiMatrix Corporation is available at www.combimatrix.com or by calling 1-800-985-CBMX (2269). Additional information about CMDX is available at www.cmdiagnostics.com or by calling 1-800-710-0624.
For more information, please click here
CombiMatrix Corporation Amit Kumar, Ph.D., President & CEO (425) 493-2000 Fax (425) 493-2010 Hayden IR Investor Relations Contact: Jeffrey Stanlis, Partner (602) 476-1821
Copyright © Benzinga.comIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Simple attraction: Researchers control protein release from nanoparticles without encapsulation: U of T Engineering discovery stands to improve reliability and fabrication process for treatments to conditions such as spinal cord damage and stroke May 28th, 2016